secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001650664-24-000034
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas Medicine Q1 net loss $62M; cash $376.8M; reni-cel adult cohort enrollment complete
--------------------------------------------------------------------------------

- Q1 2024 net loss $62.0M ($0.76/share) vs $49.0M ($0.71) in Q1 2023; collaboration revenue fell to $1.1M from $9.9M.
- Cash, equivalents, and marketable securities $376.8M at March 31, 2024; runway into 2026.
- R&D expenses rose to $48.8M from $37.8M driven by reni-cel clinical and manufacturing costs.
- Completed adult cohort enrollment in RUBY trial for sickle cell disease; enrolled multiple adolescent patients.
- Extended Bristol Myers Squibb collaboration by two years; CAFC oral arguments held for CRISPR patent interference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066424000034/0001650664-24-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066424000034/edit-20240508.htm
  HTML page:      https://secwatch.observer/filing/0001650664-24-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer